Research analysts covering NewcelX.
Recent press releases and 8-K filings for NLSP.
NewCelX CEO Issues Letter to Shareholders Outlining Strategic Vision and Milestones
NLSP
New Projects/Investments
Guidance Update
- NewCelX Ltd., a clinical-stage biopharmaceutical company, outlined its strategic focus on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, with key programs including AstroRx® for ALS, IsletRx for diabetes, and the DOXA Neuroscience and Metabolic Platform.
- The company anticipates significant clinical and strategic milestones over the next 12 months, including launching a U.S. Phase 2a clinical study for ALS, initiating a U.S. Phase 1 clinical study for IsletRx, and progressing the DOXA platform toward lead-candidate selection.
- NewCelX reported raising approximately $9 million in equity financing and warrant exercises over the past year, and management believes the company is well-capitalized to support operations for the next 12 months with an existing $25 million Equity Line of Credit (ELOC) facility.
- Pro forma shareholders’ equity as of June 30, 2025, is projected to be approximately $20 million.
Nov 4, 2025, 12:15 PM
NewCelX Ltd. Provides Business and Strategic Roadmap Update Following Merger
NLSP
M&A
New Projects/Investments
- NewCelX Ltd. (Nasdaq: NCEL) was formed in October 2025 through the merger of NLS Pharmaceutics and Kadimastem, establishing a Swiss clinical-stage biopharmaceutical company focused on neurodegenerative and metabolic diseases.
- The company's pipeline features AstroRx® for ALS, which has FDA IND approval for a planned phase IIa clinical trial, and IsletRx for insulin-dependent diabetes, with an IND for clinical trial planned for Q1 2025.
- NewCelX is also advancing the DOXA platform for rare sleep disorders and neurodegenerative diseases, currently in advanced preclinical stages with IND-enabling studies and Phase 1 IND submission planned.
Nov 3, 2025, 1:47 PM
NLS Pharmaceutics Completes Merger with Kadimastem, Renames to NewcelX
NLSP
M&A
Delisting/Listing Issues
New Projects/Investments
- NLS Pharmaceutics Ltd. completed its merger with Kadimastem Ltd. on October 30, 2025.
- The combined entity has been renamed NewcelX Ltd. and will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" on October 31, 2025.
- In connection with the merger, a 1-for-10 reverse stock split was effected, and the company's traded warrants will be delisted.
- NewcelX Ltd. will focus on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
Oct 30, 2025, 8:17 PM
NLS Pharmaceutics Expands CNS Pipeline and Secures Funding
NLSP
Product Launch
New Projects/Investments
M&A
- NLS Pharmaceutics Ltd. and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection for central nervous system (CNS) disorders.
- The AEX-6xx series integrates dual orexin receptor agonism with cathepsin H inhibition and includes AEX-635, which modulates Multidrug Resistance-Associated Protein 1 (MRP1) to potentially enhance neuroprotective effects and improve CNS drug bioavailability.
- NLS Pharmaceutics secured approximately $7 million in equity financing and a $25 million equity line of credit agreement, which are expected to fund the combined company, NewCelX, for at least the next 12 months.
- NLS and Aexon Labs are preparing for preclinical partnering and co-development discussions for the AEX-6xx series in Q4 2025.
Oct 30, 2025, 11:15 AM
NLS Pharmaceutics Expands CNS Pipeline and Bolsters Financial Position
NLSP
New Projects/Investments
M&A
Guidance Update
- NLS Pharmaceutics and Aexon Labs announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability, cognition, and neuroprotection, with investigational new drug (IND)-enabling studies being prepared.
- NLS raised approximately $7 million in equity financing and secured a $25 million equity line of credit, which, along with ongoing licensing discussions, is expected to fund the combined company, NewCelX, for at least the next 12 months.
- Following its merger with Kadimastem Ltd., NLS will operate as NewCelX Ltd., and preclinical partnering and co-development discussions for the AEX-6xx series are planned for Q4 2025.
Oct 30, 2025, 11:00 AM
NLS Pharmaceutics and Kadimastem Announce Continued BIRD Foundation Support for Diabetes Program Post-Merger
NLSP
M&A
New Projects/Investments
- NLS Pharmaceutics Ltd. and Kadimastem announced that the BIRD Foundation will continue to support the ITOL-102 cell therapy program for Type 1 Diabetes following their merger.
- The combined company, to be named NewCelX Ltd., will advance the ITOL-102 program, which aims to develop a stem-cell-derived pancreatic islet cell therapy to cure Type 1 Diabetes without lifelong immunosuppression.
- This continued support reinforces NLS's strategic focus on leveraging Kadimastem's advanced stem-cell platform to expand its pipeline into regenerative and metabolic medicine.
Oct 29, 2025, 11:30 AM
NLS Pharmaceutics and Kadimastem Announce Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
NLSP
M&A
New Projects/Investments
Management Change
- NLS Pharmaceutics and Kadimastem announced that the ITOL-102 cell therapy program for Type 1 Diabetes will continue under the combined company, NewCelX Ltd., following their merger.
- The BIRD Foundation will maintain its support for the ITOL-102 program, which aims to develop a functional, stem-cell-derived, pancreatic islet cell therapy to cure Type 1 Diabetes without lifelong immunosuppression.
- Ronen Twito, Executive Chairman and CEO of Kadimastem, will lead NewCelX as its Executive Chairman and CEO upon merger completion, signifying NLS's strategic expansion into regenerative and metabolic medicine.
Oct 29, 2025, 11:00 AM
NLS Pharmaceutics Announces Reverse Share Split, Name Change, and Merger Details
NLSP
M&A
Delisting/Listing Issues
- NLS Pharmaceutics Ltd. announced a 1-for-10 reverse share split and a name change to NewcelX Ltd.
- The company's common shares are expected to begin trading on the Nasdaq Capital Market on a post-split basis under the new trading symbol "NCEL" at market open on October 31, 2025, following the anticipated closing of its merger with Kadimastem Ltd.
- After the reverse split and merger, the company is expected to have 4,558,378 total outstanding common shares, 1,060,574 common shares issuable upon exercise of pre-funded warrants, 13,778 preferred shares, and 58,320 preferred participation certificates, all with a par value of CHF 0.05.
Oct 29, 2025, 10:00 AM
NLS Pharmaceutics and Kadimastem Announce Merger Completion Conditions Met
NLSP
M&A
Delisting/Listing Issues
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. have announced that all material conditions precedent for their merger have been fulfilled or waived.
- The closing of the merger is scheduled for October 30, 2025.
- The combined company will be named NewCelX Ltd. and is expected to be listed on the Nasdaq Capital Market under the ticker symbol "NCEL", beginning October 31, 2025.
- Kadimastem's ordinary shares will be delisted from the Tel Aviv Stock Exchange (TASE) on October 31, 2025.
- The final exchange ratio is 0.706 NLS common shares for each Kadimastem ordinary share.
Oct 29, 2025, 7:53 AM
NLS Pharmaceutics Announces Reverse Share Split, Name Change, and Merger Details
NLSP
M&A
Proxy Vote Outcomes
- NLS Pharmaceutics Ltd. announced a 1-for-10 reverse share split and a name change to NewcelX Ltd., with a new trading symbol NCEL, in connection with its proposed merger with Kadimastem Ltd..
- The reverse split is expected to become effective in Switzerland on October 30, 2025, and on Nasdaq at market open on October 31, 2025.
- These corporate actions, including the capital measures, were approved at an extraordinary shareholders' meeting held on September 29, 2025.
- Following the reverse split and merger, the company's capital structure will be as follows:
| Metric | Post-Merger & Reverse Split |
|---|---|
| Registered Share Capital (CHF) | 282,908.80 |
| Common Shares (Number) | 5,533,183 |
| Preferred Shares (Number) | 124,993 |
| Registered Participation Capital (CHF) | 3,032.40 |
| Preferred Participation Certificates (Number) | 60,648 |
| Total Outstanding Common Shares (Number) | 4,558,378 |
| Common Shares Issuable from Warrants (Number) | 1,060,574 |
| Total Outstanding Preferred Shares (Number) | 13,778 |
| Total Outstanding Preferred Participation Certificates (Number) | 58,320 |
Oct 29, 2025, 1:21 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more